Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells - Top-Institutions - MDSpire

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells

  • By

  • Susan Gellert

  • Bastian Kruse

  • Johannes Peters

  • Susanne Bonifatius

  • Thomas Tüting

  • Anthony C. Buzzai

  • June 22, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #2

    Mass General Brigham Cancer Institute
    Mass General Brigham Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology

  • #3

    Rutgers Cancer Institute of New Jersey
    Rutgers Cancer Institute of New Jersey

    New Brunswick, NJ

    Key Differentiators

    • Oncology

  • #4

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology

  • #5

    Vanderbilt University
    Vanderbilt University

    Nashville, TN

    Key Differentiators

    • Oncology

Original Source(s)

Oncolytic virotherapy counteracts the selection of IFN-unresponsive cancer cells post-immunotherapy but is limited by the emergence of dedifferentiated cancer cells

  • by Susan Gellert, Bastian Kruse, Johannes Peters, Susanne Bonifatius, Thomas Tüting, Anthony C. Buzzai

  • June 22, 2026

Related Content

A Case Report of follicular dendritic cell sarcoma

Orbital metastasis from breast carcinoma: structured literature review and report of four cases

Stereotactic versus whole-brain radiotherapy combined with immunotherapy in driver gene–negative NSCLC with brain metastases: a real-world IPTW analysis